Modulation of AMPK Significantly Alters Uveal Melanoma Tumor Cell Viability

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Uveal melanoma (UM) exhibits poor response to current therapies.
• Adenosine monophosphate-activated protein kinase (AMPK) is crucial for cell growth and survival.
• Targeting the AMPK pathway presents a novel therapeutic strategy for UM.

Purpose of the Study:

• To investigate the effects of modulating the AMPK pathway on UM cells.
• To explore AMPK as a potential therapeutic target for uveal melanoma.

Main Methods:

• In silico analyses (KEGG, GSEA) to compare UM and normal melanocytes.
• In vitro assays (XTT) to assess cell viability and proliferation.
• Treatment of UM cell lines with an AMPK activator (A-769662) and an inhibitor (dorsomorphin).

Main Results:

• AMPK signaling pathway genes were differentially regulated in UM.
• AMPK activation by A-769662 decreased UM cell viability in a dose-dependent manner.
• AMPK inhibition by dorsomorphin potently reduced UM cell viability, with significant effects at low doses.

Conclusions:

• AMPK's role in cancer is context-dependent.
• Modulating the AMPK pathway offers a new therapeutic perspective for UM.
• Targeting AMPK may lead to novel treatment approaches to improve UM survival.